Royalty Pharma EVP Marshall Urist Sells ~$236K in Class A Shares Under Rule 10b5-1 Plan

Executive Summary

On October 5, 2026, Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc (NASDAQ: RPRX), filed a Form 4 detailing the open-market sale of 4,126 Class A Ordinary Shares at an execution price of $57.10 per share, yielding gross proceeds of approximately $235,595.

Transaction Details & Plan Structure

• Transaction Date: October 5, 2026
• Filing Date: October 5, 2026
• Nature of Trade: Direct open-market sale (Transaction Code S).
• Trading Plan: The trade was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2026.
• Direct vs. Indirect Holdings: While direct ownership of Class A Ordinary Shares decreased to 0, the reporting owner retains 19,020 shares indirectly held via an IRA.
• Broader Economic Exposure: As noted in the filing remarks, Mr. Urist and controlled family entities hold substantial partnership and Class E interests exchangeable into approximately 3.8 million Class A Ordinary Shares (2,444,120 via RPI US Partners 2019, LP and 1,356,528 via Royalty Pharma Holdings Ltd subject to vesting).

Market Signaling & Sentiment

This transaction carries Low informational significance for investors. The sale represents a modest dollar amount ($235.6K) executed automatically under an established Rule 10b5-1 plan, and it comprises a negligible fraction of Mr. Urist's overall economic exposure to the company.